JPH08189930A - Method for measuring comfortableness - Google Patents

Method for measuring comfortableness

Info

Publication number
JPH08189930A
JPH08189930A JP1653795A JP1653795A JPH08189930A JP H08189930 A JPH08189930 A JP H08189930A JP 1653795 A JP1653795 A JP 1653795A JP 1653795 A JP1653795 A JP 1653795A JP H08189930 A JPH08189930 A JP H08189930A
Authority
JP
Japan
Prior art keywords
comfort
increase
measured
measuring
immune function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1653795A
Other languages
Japanese (ja)
Inventor
Tomoshi Kimura
知史 木村
Chihoko Suga
千帆子 菅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Chemical Industries Inc
Original Assignee
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Chemical Industries Inc filed Critical Pola Chemical Industries Inc
Priority to JP1653795A priority Critical patent/JPH08189930A/en
Publication of JPH08189930A publication Critical patent/JPH08189930A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE: To quantitatively and easily measure comfortableness so as to establish a cosmetic evaluating method by using the variation of the immunological function, especially, the increase of secretory immunoglobulin, appearance and increase of a CD receptor, and increase of the activity of natural killer cells as indexes. CONSTITUTION: Comfortableness is measured by using the variation of the immunological function, especially, the increase of secretory immunoglobulin, appearance and increase of a CD receptor, and increase of the activity of natural killer cells as indexes. Namely, the secreted amounts of IgA having H α- chains and IgE having ε-chains of the immunoglobulin are measured as the IgA concentration of secretory immunoglobulin and IgE concentration in blood and the increasing rate of IgA and decreasing rate of IgE are used as the index of comfortablenss. In addition, the increasing rate of the appearing amount of CD receptors and increasing rate of the activity of natural killer cells are also used as the index of comfortableness. To be concrete, they can be used as indexes for evaluating cosmetics for skin, cosmetics for hair, cleaning agents, and bathing agents.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は心地よさの測定法に関
し、更に詳しくは免疫機能の変化を指標とする心地よさ
の測定法に関する。加えて、本発明は心地よさを指標と
する香粧品及び医療品の評価法に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for measuring comfort, and more particularly to a method for measuring comfort using changes in immune function as an index. In addition, the present invention relates to a method for evaluating cosmetics and medical products using comfort as an index.

【0002】[0002]

【従来の技術】心地よさは人間生活を円滑に行う上で非
常に重要な事である事は万人の認めるところである。人
間は心地よさが失われて、精神的な圧迫を感ずるような
状態、例えば、極度のストレス状態に長時間置かれる
と、精神的のみならず身体的にも変調をきたしてしま
う。そのいい例が、過労症等に代表される現代病であ
る。これらは、知らず知らずの内に人間の心身を蝕み、
ついには命をも奪ってしまう事も有り得る恐ろしい疾病
である。
2. Description of the Related Art It is universally accepted that comfort is very important for smooth human life. When human beings lose their comfort and feel emotional pressure, for example, when they are left in an extremely stressed state for a long time, they are not only mentally but physically altered. A good example is the modern illness represented by overwork. These unknowingly erode the human mind and body,
It is a terrible disease that can eventually take lives.

【0003】従って、これら過度のストレス状態の対極
にある、リラックス状態言い替えれば、心地よさの程度
を知る事はこれらの疾病から身を守る上から非常に意義
深い事である。
Therefore, the opposite of these excessive stress states, that is, the relaxed state, in other words, knowing the degree of comfort is very significant for protecting oneself from these diseases.

【0004】しかしながら、リラックスの程度、即ち心
地よさの程度を測る事は、非常に困難が伴われた。これ
は、心地よさが概念的な現象であり、物理的又は生理的
現象として客観的に捉える事が困難であったからであ
る。この、心地よさを測定する方法として、脳波取り分
けα波を測定する事が行われたが、α波の測定は煩雑な
上、バラツキを少なくするための大がかりな測定環境と
大がかりな装置が必要であったため、容易に行う事は出
来なかった。又、測定結果の解析もその解釈が難しい
上、定量性に問題があった。
However, it has been very difficult to measure the degree of relaxation, that is, the degree of comfort. This is because comfort is a conceptual phenomenon and it was difficult to objectively grasp it as a physical or physiological phenomenon. As a method of measuring comfort, brain waves were separated and α waves were measured, but the measurement of α waves is complicated, and a large measurement environment and a large device to reduce variations are required. I couldn't do it easily because it was there. In addition, the analysis of the measurement result is difficult to interpret, and there is a problem in quantitativeness.

【0005】一方、免疫機能と精神状態の関連について
は、極度のストレス状態に於いては、免疫機能が低下す
る場合がある事は知られていたが、心地よさと免疫機能
の関係については全く知られていなかった。更に、香粧
品の評価は、例えば、皮膚化粧料を水分保持能やシワ改
善作用、メラニン生成阻害作用等の機能で評価したり、
洗浄料を洗浄力で評価したり、アンケートによってパネ
ラーに気に入るか気に入らないかで評価したりする事は
行われていたが、心地よさを指標に評価する事は行われ
ていなかった。これは、香粧品が水分保持作用、シワ改
善作用、メラニン生成阻害作用、洗浄力と言った機能以
外の部分、即ち、使って気持ちがよいとかリラックスし
たとか言うソフト的なメリットの部分にも大きな存在価
値があるにも係わらず、このソフト的なメリットを客観
的且つ定量的に測定する手段が知られていなかったため
である。
On the other hand, regarding the relationship between the immune function and the mental state, it has been known that the immune function may decrease in an extremely stressed state, but the relationship between comfort and immune function is completely known. It wasn't done. Further, the evaluation of cosmetics may be performed, for example, by evaluating the skin cosmetics with functions such as water retention ability, wrinkle improving action, and melanin production inhibiting action.
The cleaning power was evaluated by the detergency, and the questionnaire was used to evaluate whether the panelists liked or disliked it, but the comfort level was not evaluated. This is a big part of the cosmetics other than the functions such as water retention, wrinkle improvement, melanin production inhibition, and detergency, that is, the soft merit of feeling comfortable or relaxing. This is because there is no known means for objectively and quantitatively measuring this soft merit despite the existence value.

【0006】[0006]

【発明が解決しようとする課題】本発明はかかる状況を
鑑みて為されたものであり、定量的且つ簡易に心地よさ
を測定する手段を提供する事を課題とする。更に、この
定量化された心地よさを指標に香粧品を評価する方法を
提供する事を課題とする。
SUMMARY OF THE INVENTION The present invention has been made in view of such a situation, and an object thereof is to provide means for quantitatively and easily measuring comfort. Further, it is an object to provide a method for evaluating a cosmetic product using the quantified comfort as an index.

【0007】[0007]

【課題を解決するための手段】上記課題を解決するため
に、本発明者らは心地よさが人の生理に及ぼす影響につ
いて研究を重ねた結果、免疫機能の変化、取り分け分泌
型免疫グロブリンの増加、CDレセプターの発現増加、
ナチュラル・キラー細胞活性の増加等感染に対する免疫
機能の亢進と強い因果関係がある事を見いだし発明を完
成させた。即ち、本発明は免疫機能の変化を指標とする
心地よさの測定法に関するものである。
[Means for Solving the Problems] In order to solve the above problems, the inventors of the present invention have conducted repeated studies on the effect of comfort on human physiology, and as a result, have altered immune functions and, in particular, increased secretory immunoglobulins. , Increased expression of CD receptor,
The inventors have found that there is a strong causal relationship with the enhancement of immune function against infection, such as an increase in natural killer cell activity, and completed the invention. That is, the present invention relates to a method for measuring comfort using a change in immune function as an index.

【0008】本発明の心地よさの測定法に関する免疫機
能は、免疫全般に亘っているが、主だったものは、免疫
グロブリンの増減、表面レセプターの発現量、細胞障害
活性等である。以下、これらと心地よさの関係について
詳細に説明する。
The immune function relating to the method for measuring comfort of the present invention covers immunity in general, but the major ones are increase / decrease of immunoglobulin, surface receptor expression level, cytotoxic activity and the like. Hereinafter, the relationship between these and comfort will be described in detail.

【0009】(1)免疫グロブリンと心地よさの関係 免疫グロブリン(Ig)は抗体としての分子構造を持っ
ているタンパク質の総称であり、補体結合性、細胞への
付着性、胎盤通過性等の生物学的活性に係わるH鎖の構
造により、人の免疫グロブリンは大きく分けて、5つに
分けられる。即ち、H鎖がガンマ鎖であるIgG、アル
ファー鎖であるIgA、ミュー鎖であるIgM、デルタ
鎖であるIgD、イプシロン鎖であるIgEの5つであ
る。ここで、IgGは両生類以上の高等動物で最も一般
的な免疫グロブリンで2分子で1分子の補体と結合する
事が知られている。又、胎盤通過性がある。IgAは外
分泌液中の主要な免疫グロブリンで、補体とは結合せず
胎盤通過性もない。IgMは最も原始的な免疫グロブリ
ンで1分子で1分子の補体と結合し溶血活性が高い。
又、胎盤通過性は殆どない。IgDは分子量約17万の
免疫グロブリンとして独立したH鎖を持っているが抗体
活性は知られていない。IgEは多糖類を多く含んでい
る事が知られている。主として腸管や気管のリンパ組織
で作られアナフィラキシーを起こさせる抗体として知ら
れている。
(1) Relationship between Immunoglobulin and Comfort Immunoglobulin (Ig) is a general term for proteins having a molecular structure as an antibody, such as complement fixation, cell adhesion, and placenta passage. Human immunoglobulins are roughly divided into five types according to the structure of the H chain involved in biological activity. That is, the H chain is IgG which is a gamma chain, IgA which is an alpha chain, IgM which is a mu chain, IgD which is a delta chain, and IgE which is an epsilon chain. Here, IgG is the most common immunoglobulin in higher animals such as amphibians and is known to bind to one molecule of complement in two molecules. It also has a placenta-passing property. IgA is the major immunoglobulin in exocrine fluid, does not bind complement and is not placental. IgM is the most primitive immunoglobulin, and it binds to one molecule of complement in one molecule and has high hemolytic activity.
Also, there is almost no placental passage. IgD has an independent H chain as an immunoglobulin having a molecular weight of about 170,000, but its antibody activity is unknown. It is known that IgE contains many polysaccharides. It is known as an antibody mainly produced in lymphatic tissues of the intestinal tract and trachea to cause anaphylaxis.

【0010】これらの免疫グロブリンの内、本発明の測
定法では、IgAの上昇率及びIgEの減少率を心地よ
さの指標とする。本発明者らは任意に選び出したパネラ
ーについて、心地よい環境下及び心地よくない環境下に
於けるIgA及びIgEの分泌量を唾液中の分泌型免疫
グロブリンA(sIgA)の濃度、血中のIgE濃度と
して測定した結果、心地よさの程度に相関してsIgA
の濃度が上昇しIgEの濃度が減少する事を見いだし
た。即ち、このことから、これらの濃度変化を知る事に
より心地よさの変化を定量的に測定出来る事が判る。
Among these immunoglobulins, in the assay method of the present invention, the rate of increase in IgA and the rate of decrease in IgE are used as indices of comfort. With respect to arbitrarily selected panelists, the present inventors have determined the secretory immunoglobulin A (sIgA) concentration in saliva and the IgE concentration in blood as the secretion amounts of IgA and IgE in a comfortable environment and an uncomfortable environment. As a result of measurement, sIgA correlates with the degree of comfort
It was found that the concentration of E. coli increased and the concentration of IgE decreased. That is, it can be understood from this that the change in comfort can be quantitatively measured by knowing the change in concentration.

【0011】(2)CDレセプターの発現量と心地よさ
の関係 CDレセプターは免疫担当抗体表面或いは顆粒球表面に
存在するレセプターで異物認識等の働きに重要な役目を
担っている。従って、免疫機能が亢進しているときや感
染等して生体防御機構が働いているときCDレセプター
の発現量は増加する。CDレセプターはその構造や機能
により多種に分類されており、これらはそれぞれのモノ
クロナール抗体を用いる事により、その発現量を抗原抗
体反応により測定することが出来る。本発明者が任意に
選んだパネラーを用いて心地よさとこれらのレセプター
との関係を調査した結果、心地よさの程度に相関して各
種CDレセプターの発現量が増大する事が判明した。即
ち、このことよりCDレセプター発現量の変化を知る事
により心地よさの程度を定量的に測定できる事が判る。
(2) Relationship between CD receptor expression level and comfort CD receptor is a receptor existing on the surface of immunocompetent antibody or on the surface of granulocytes, and plays an important role in recognizing foreign substances. Therefore, the expression level of the CD receptor increases when the immune function is enhanced or when the biological defense mechanism is working due to infection or the like. CD receptors are classified into various types according to their structures and functions, and their expression levels can be measured by an antigen-antibody reaction by using respective monoclonal antibodies. As a result of investigating the relationship between comfort and these receptors using a panel arbitrarily selected by the present inventor, it was found that the expression levels of various CD receptors increased in correlation with the degree of comfort. That is, it can be understood from this that the degree of comfort can be quantitatively measured by knowing the change in the CD receptor expression level.

【0012】(3)細胞障害活性と心地よさの関係 細胞障害活性は顆粒球やナチュラル・キラー細胞の防御
機構の主たる活性である。即ち、体内に侵入した異種生
物を貪食したり、細胞障害性因子やプロテアーゼで攻撃
したりする事である。即ち、これら免疫に係わる効果細
胞の防御機構が活性化していればこの様な細胞障害活性
は高くなる。この様な細胞障害活性は血液を取り出し、
これより顆粒球を分離し、これにマーキングした標的細
胞、例えばオプソニン化したザイモザンや51Cr等の放
射性同位体等でラベルした癌細胞を加え、効果細胞の発
する酸素ラジカルをルミノールやルシェフェリン等の化
学発光物質の発光強度を測定したり、破壊された標的か
ら漏出する放射性同位体を放射強度として測定したりす
る事により定量的に測定できる。本発明者らは任意に選
んだパネラーを用いて、細胞障害活性と心地よさの関係
を調査したところ、心地よさの程度と細胞障害活性の増
加率の間に性の相関関係を見いだした。即ち、細胞障害
活性の変化量を知る事により、心地よさの定量的な変化
が判る事を見いだした。
(3) Relationship between cytotoxic activity and comfort Cytotoxic activity is the main activity of the defense mechanism of granulocytes and natural killer cells. That is, it phagocytoses a heterologous organism that has invaded the body, or attacks with a cytotoxic factor or protease. That is, if the defense mechanism of these effecting cells related to immunity is activated, such cytotoxic activity is increased. Such cytotoxic activity removes blood,
Granulocytes are separated from this, and the marked target cells, for example, cancer cells labeled with radioisotopes such as opsonized zymosan and 51 Cr are added, and the oxygen radicals emitted by the effector cells such as luminol and luscheferin are added. It can be quantitatively measured by measuring the emission intensity of the chemiluminescent substance or by measuring the radioisotope leaked from the destroyed target as the emission intensity. The present inventors investigated the relationship between cytotoxic activity and comfort using arbitrarily selected panelists, and found a sexual correlation between the degree of comfort and the rate of increase in cytotoxic activity. That is, it was found that by knowing the amount of change in cytotoxic activity, the quantitative change in comfort can be understood.

【0013】以上をまとめると、心地よさの程度が増大
するにしたがって、免疫機能が活性化している事が判
る。従って、免疫機能の活性化度を測定する事により心
地よさを測定できる事が判る。言い替えれば、今まで色
々な主観的な言葉で、様々な情緒的な指標で表現されて
きた心地よさを定量的に且つ一元的な数値として表現で
きる事が本発明の特徴である。免疫機能の指標としては
上記に挙げたものが好適に例示できるが、本発明はこれ
らに限定されるものではない。かくして得られた心地よ
さは、香粧品等のいわゆるソフト的なメリット、例え
ば、使い心地が気持ちいいとか、香りが心地よいとか、
洗い上りが心地よいと言うような事項の評価の指標とし
て用いることが出来る。具体的には、香粧品の使用の前
後の免疫機能を測定し、その上昇率が高い香粧品程、そ
の使用に際して心地よさを促すものであり、ソフト的な
メリットの大きいものであると評価できる。ここで、香
粧品とは、クリーム、乳液、化粧水、ファンデーショ
ン、パウダー、アイカラー、リップカラー、チークカラ
ー等に代表される皮膚用化粧品、ヘアトニック、ヘアリ
ンス、ヘアカラー等の頭髪用化粧品、シャンプー、石
鹸、歯磨き、口腔清浄料等の洗浄料、入浴料、ルームフ
レグランス、カーフレグランス、香水類等のフレグラン
ス料及びこれらの原材料の総称を意味する。更に本発明
の測定法は、医療品についても用いいることが出来る。
医療品の中には、例えば冷湿布や温湿布の様に実際の抗
炎症効果等の薬効以外の使用感が重要な要素となるもの
が少なくなく、本発明ではこれらの使用感の良さを心地
よさとして測定することが出来る。かかる医療品として
は、湿布剤の様な貼付剤、抗炎症外用剤や鎮痛外用剤の
様な皮膚外用剤、うがい薬、マッサージ機、赤外線照射
機等が例示できる。本発明の方法で測定される心地よさ
は、香粧品や医療品に限らず、住居の住み心地の良さ、
車の乗り心地の良さ、洗濯物の洗濯仕上がりの心地よさ
等の様々な商品のソフト的メリットの評価の指標とする
事が出来る。
In summary, it can be seen that the immune function is activated as the degree of comfort increases. Therefore, it is understood that the comfort can be measured by measuring the activation degree of the immune function. In other words, it is a feature of the present invention that the comfort that has been expressed by various emotional indexes by various subjective words can be expressed quantitatively and as a unified numerical value. The above-mentioned examples can be preferably exemplified as the index of the immune function, but the present invention is not limited thereto. The comfort thus obtained is a so-called soft merit of cosmetics, for example, whether it is comfortable to use or has a pleasant scent.
It can be used as an index for evaluation of items that make washing comfortable. Specifically, the immune function before and after the use of a cosmetic product is measured, and a cosmetic product having a higher rate of increase promotes comfort in use, and can be evaluated as having a great soft merit. . Here, the cosmetics include skin cosmetics represented by creams, milky lotions, lotions, foundations, powders, eye colors, lip colors, cheek colors, hair tonics, hair rinses, hair color cosmetics, shampoos. , Soap, toothpaste, cleansing agents such as mouthwash, bathing agents, room fragrances, car fragrances, fragrances such as perfumes, and the general term for these raw materials. Furthermore, the measuring method of the present invention can also be used for medical products.
There are many medical products such as cold compresses and warm compresses, in which the feeling of use other than the medicinal effects such as the actual anti-inflammatory effect is an important factor, and in the present invention, the good feeling of use is comfortably felt. It can be measured as Examples of such medical products include patches such as poultices, external skin preparations such as anti-inflammatory external preparations and analgesic external preparations, gargles, massage machines, and infrared irradiation machines. Comfort measured by the method of the present invention is not limited to cosmetics and medical products, comfort of living,
It can be used as an index for evaluating the soft merit of various products, such as the comfort of a car and the comfort of finished laundry.

【0014】[0014]

【実施例】上記の免疫機能の変化と心地よさの関係につ
いて、実施例を挙げながら更に詳しく説明する。
EXAMPLES The relationship between the above-mentioned changes in immune function and comfort will be described in more detail with reference to Examples.

【0015】実施例1 任意に選んだパネラー5名に、5℃の恒温室に30分滞
在して貰い血液と唾液を採取した後に、25℃に30分
間滞在して貰い再び血液と唾液を採取した。これらの採
取した唾液と血液より各種免疫機能を測定し、その変化
を調べた。その一日後、同じパネラーを用いて、25℃
に30分滞在した後5℃に30分滞在した場合の各種免
疫機能の変化を同様に求めた。
Example 1 Five arbitrarily selected panelists stayed in a thermostatic chamber at 5 ° C for 30 minutes to collect blood and saliva, and then stayed at 25 ° C for 30 minutes to collect blood and saliva again. did. Various immune functions were measured from these collected saliva and blood, and their changes were examined. One day later, using the same panel, 25 ℃
Similarly, changes in various immune functions when staying at 30 ° C. for 30 minutes and then at 5 ° C. for 30 minutes were similarly determined.

【0016】唾液中の分泌型免疫グロブリンA(sI
gA)の変化 採取した唾液中のsIgAを測定した。sIgA測定
は、西田らのサンドウィッチ抗体法に準じて行った
(「医学のあゆみ」129(11)、767ー770、
1984)。
Secretory immunoglobulin A (sI in saliva
Change of gA) sIgA in saliva collected was measured. The sIgA measurement was carried out according to the sandwich antibody method of Nishida et al. (“Medical Ayumi” 129 (11), 767-770,
1984).

【0017】以下に具体的に説明する。なお、以下で用
いた固相化抗体は、次のようにして作成した。ポリスチ
レンボール(直径6.5mm、イチコ製)の表面上に未
精製山羊抗ヒトαー鎖抗体(IgG分画、CAPPEL
Co.製)を物理的に吸着させ不溶化させた。即ち、
上記抗体0.03mg/mlを含む0.1Mリン酸緩衝
液(pH7.5)中にポリスチレンボール300個を浸
し、1晩4℃で保存した。更に、0.1%ウシ血清アル
ブミン(以下、「BSA」という)を含む0.1Mリン
酸緩衝液(pH7.5)に1昼夜浸した後、0.1Mリ
ン酸緩衝液(pH7.5)で洗浄し固相化抗体とした。
保存は4℃とした。
A detailed description will be given below. The immobilized antibody used below was prepared as follows. Unpurified goat anti-human α-chain antibody (IgG fraction, CAPPEL) on the surface of polystyrene balls (diameter 6.5 mm, manufactured by Ichiko)
Co. (Manufactured by K.K.) was physically adsorbed and insolubilized. That is,
300 polystyrene balls were immersed in a 0.1 M phosphate buffer (pH 7.5) containing 0.03 mg / ml of the above antibody and stored overnight at 4 ° C. Furthermore, after soaking in a 0.1 M phosphate buffer (pH 7.5) containing 0.1% bovine serum albumin (hereinafter referred to as “BSA”) for one day and night, a 0.1 M phosphate buffer (pH 7.5) It was washed with and used as a solid-phased antibody.
Storage was at 4 ° C.

【0018】続いて、上記固相化抗体を用いて免疫グロ
ブリンを定量する方法を説明する。0.2%BSA、1
%NaCl及び0.05%ツィーン20を含む0.05
Mリン酸緩衝液(pH7.5、以下「緩衝液A」とい
う)で希釈した標準分泌型免疫グロブリンA(sーIg
A、CAPPEL Co.製)溶液100μl、または
唾液を緩衝液Aで400倍希釈した検体100μlを試
験管に注入した。
Next, a method for quantifying immunoglobulin using the above-mentioned immobilized antibody will be described. 0.2% BSA, 1
0.05 with% NaCl and 0.05% Tween 20
Standard secretory immunoglobulin A (s-Ig) diluted with M phosphate buffer (pH 7.5, hereinafter referred to as "buffer A")
A, CAPPEL Co. 100 μl of a solution or 100 μl of a sample obtained by diluting saliva 400 times with buffer A was injected into a test tube.

【0019】この試験管に、第1抗体として上記固相化
抗体(ポリスチレンボール1個)を加え、次いで第2抗
体として、緩衝液Aにて400倍希釈したペルオキシダ
ーゼ標識ウサギ抗SC抗体(DAKOPATTS社製)
300μlを添加した。37℃、4時間インキュベーシ
ョンを行った後、緩衝液A1mlにて3回ポリスチレン
ボールの洗浄を行った。
The above immobilized antibody (one polystyrene ball) was added to this test tube as the first antibody, and then, as the second antibody, a peroxidase-labeled rabbit anti-SC antibody (DAKOPATTS) diluted 400-fold with buffer A. Made)
300 μl was added. After incubation at 37 ° C. for 4 hours, polystyrene balls were washed 3 times with 1 ml of buffer A.

【0020】その後、0.25%ーフェニレンジアミン
及び0.015%過酸化水素を含む0.1Mクエン酸ー
0.1Mリン酸緩衝液(pH4.7)250μlを入れ
た試験管に上記ポリスチレンボールを移して、37℃で
30分インキューベートし、1規定の硫酸2mlを試験
管に加えて酵素反応を停止させ、492nmにて吸光度
を測定した。
Then, the polystyrene ball was placed in a test tube containing 250 μl of 0.1 M citric acid-0.1 M phosphate buffer (pH 4.7) containing 0.25% phenylenediamine and 0.015% hydrogen peroxide. Was transferred, incubated at 37 ° C. for 30 minutes, 2 ml of 1N sulfuric acid was added to the test tube to stop the enzymatic reaction, and the absorbance was measured at 492 nm.

【0021】測定結果を表1に示す。これより、5℃よ
り25℃に移った場合、即ち心地よさが増大している場
合には、分泌型免疫グロブリンの濃度は上昇し、その逆
の場合は低下している事が判る。これより、免疫グロブ
リンの変化量と心地よさの変化量が良い相関関係にある
事が判る。即ち、sIgAの変化量を測定する事により
心地よさの変化量を定量出来る事が判る。尚、5℃より
25℃に移る実験に於いて採血したパネラーA、Bの血
液について、臨床検査受託業者に依頼してIgEの濃度
を測定して貰ったところ、それぞれ5℃での血液中の濃
度に対して、25℃での濃度は95%及び93%と減少
していることが判明し、IgEの濃度の減少も心地よさ
の指標に使えることが判明した。
The measurement results are shown in Table 1. From this, it is understood that the concentration of secretory immunoglobulin increases when the temperature shifts from 5 ° C. to 25 ° C., that is, when the comfort increases, and decreases in the opposite case. From this, it can be seen that there is a good correlation between the amount of change in immunoglobulin and the amount of change in comfort. That is, it is understood that the amount of change in comfort can be quantified by measuring the amount of change in sIgA. Regarding the blood of panelists A and B collected in the experiment of shifting from 5 ° C to 25 ° C, we asked a clinical laboratory contractor to measure the concentration of IgE. It was found that the concentration at 25 ° C decreased to 95% and 93% with respect to the concentration, and it was also found that the decrease in the concentration of IgE can be used as an index of comfort.

【0022】[0022]

【表1】 [Table 1]

【0023】CDレセプターと心地よさの関係 CDレセプターの内、CD18、CD20、CD38に
ついて、上記の血液中の発現量を抗原抗体反応により測
定した。測定そのものは測定業者に委託して行った。こ
れらの発現量の測定については、既にそれを業としてい
るものが存在しており、容易に行える。結果を表2に示
す。この結果より何れのCDレセプターも心地よさの増
大・減少に応じて増大・減少している事が判る。即ち、
CDレセプターの発現量の変化を測定する事により心地
よさの変化を測定することが出来る。
Relationship between CD receptor and comfort Among CD receptors, CD18, CD20 and CD38 were assayed for their expression levels in blood by antigen-antibody reaction. The measurement itself was outsourced to a measurement company. Regarding the measurement of these expression levels, there are some that have already done this and can be easily performed. Table 2 shows the results. From these results, it can be seen that all CD receptors increase / decrease according to the increase / decrease in comfort. That is,
The change in comfort can be measured by measuring the change in expression level of the CD receptor.

【0024】[0024]

【表2】 [Table 2]

【0025】ナチュラル・キラー細胞と心地よさの関
係 セオ・フェランテ等の方法を用いて(Seo Ferr
ante et.al.、Int.Archs.All
ergy appl.Immun.85、410−41
5、(1988))51CrでラベルしたK562細胞を
標的細胞としてナチュラル・キラー細胞由来の細胞障害
活性を調べた。即ち100μキューリーのクロム酸ナト
リウムを37℃で1時間作用させ、その後MEMで3回
洗浄したK562細胞を1×105個/mlの濃度にM
EMで希釈しターゲット細胞分散液とした。このターゲ
ット細胞液0.1mlと上記の採取した血液0.1ml
を混合し、37℃で5%炭酸ガス混在下4時間インキュ
ベートし、800Gで遠心分離し、細胞障害により上清
中へ漏出したクロムの放射活性をガンマカウンターで測
定した。結果を表3に示す。これより心地よさの増大・
減少に応じて細胞障害活性も増大・減少している事が判
る。細胞障害活性の変化量を測定すれば心地よさの変化
量が測定できる事が判る。
Relationship between natural killer cells and comfortability Using the method of Seo Ferrante (Seo Ferrr
ante et. al. , Int. Archs. All
ergy appl. Immun. 85, 410-41
5, (1988)) 51 Cr-labeled K562 cells were used as target cells to examine the cytotoxic activity derived from natural killer cells. That is, 100 μ curie of sodium chromate was allowed to act at 37 ° C. for 1 hour, and then K562 cells washed 3 times with MEM were concentrated to a concentration of 1 × 10 5 cells / ml.
It was diluted with EM to obtain a target cell dispersion liquid. 0.1 ml of this target cell liquid and 0.1 ml of the blood collected above
Were mixed, incubated at 37 ° C. in the presence of 5% carbon dioxide gas for 4 hours, centrifuged at 800 G, and the radioactivity of chromium leaked into the supernatant due to cell damage was measured with a gamma counter. The results are shown in Table 3. More comfortable than this
It can be seen that the cytotoxic activity also increases / decreases in accordance with the decrease. It can be seen that the amount of change in comfort can be measured by measuring the amount of change in cytotoxic activity.

【0026】[0026]

【表3】 [Table 3]

【0027】実施例2 任意に選んだパネラー5名を25℃の恒温室に1時間滞
在させた。最初の30分は何もせず、血液と唾液を採集
した後30分間音楽(モーツァルト「アイネ・クライネ
・ナハトムジーク」)を聞かせ、再び血液と唾液を採取
した。これらの唾液と血液について実施例1と同様の測
定を行った。結果を表4に示す。これより、実施例1と
同様心地よさの変化量に応じて免疫機能も変化している
事が判る。従って、免疫機能の変化量を測定すれば心地
よさの変化量が測定できる事が判る。
Example 2 Five panelists arbitrarily selected were allowed to stay in a thermostatic chamber at 25 ° C. for 1 hour. Nothing was done for the first 30 minutes, and after collecting blood and saliva, he listened to music (Mozart "Aine Kleine Nachtomzig") for 30 minutes and collected blood and saliva again. The same measurement as in Example 1 was performed on these saliva and blood. The results are shown in Table 4. From this, it can be seen that the immune function also changes according to the amount of change in comfort, as in Example 1. Therefore, it is understood that the comfort variation can be measured by measuring the immune function variation.

【0028】[0028]

【表4】 [Table 4]

【0029】実施例3 任意に選んだパネラー5名を25℃の恒温室に1時間滞
在させた。最初の30分は何もせず、血液と唾液を採集
した後30分間香料(フェネチルアルコール、0.1m
g/m3)を流し、再び血液と唾液を採取した。これら
の唾液と血液について実施例1と同様の測定を行った。
結果を表5に示す。これより、実施例1と同様心地よさ
の変化量に応じて免疫機能も変化している事が判る。従
って、免疫機能の変化量を測定すれば心地よさの変化量
が測定できる事が判る。
Example 3 Five arbitrarily selected panelists were allowed to stay in a thermostatic chamber at 25 ° C. for 1 hour. Do nothing for the first 30 minutes, collect blood and saliva for 30 minutes, then add perfume (phenethyl alcohol, 0.1 m
g / m 3 ) and blood and saliva were collected again. The same measurement as in Example 1 was performed on these saliva and blood.
The results are shown in Table 5. From this, it can be seen that the immune function also changes according to the amount of change in comfort, as in Example 1. Therefore, it is understood that the comfort variation can be measured by measuring the immune function variation.

【0030】[0030]

【表5】 [Table 5]

【0031】実施例4 任意に選んだ10名のパネラーを用いて、表6に示す2
種のシャンプーについて上記と同様に使用前後の唾液中
のsIgAを指標に免疫機能を測定した。併せて、シャ
ンプーの好みについてアンケートによって調査した。結
果を表7に示す。これより、好まれ易いシャンプーの方
が使用後の免疫上昇率が大きい事が判る。別途、専門パ
ネラー5名の合議でこの2種のシャンプーの洗浄力の評
価を行った。結果は両者間に洗浄力の差は見られなかっ
た。これらより、機能以外の部分に潜むメリットを本発
明の方法によれば的確に評価できる事が判る。
Example 4 2 shown in Table 6 using 10 panelists selected arbitrarily.
As for the shampoo of each species, the immune function was measured using sIgA in saliva before and after use as an index in the same manner as above. At the same time, a questionnaire survey was conducted on shampoo preferences. The results are shown in Table 7. From this, it can be seen that shampoo, which is more preferred, has a higher immunity increase rate after use. Separately, the detergency of these two types of shampoos was evaluated by a panel of five expert panelists. As a result, no difference in detergency was found between the two. From these, it can be seen that the merit hidden in the portion other than the function can be accurately evaluated by the method of the present invention.

【0032】[0032]

【表6】 [Table 6]

【0033】[0033]

【表7】 [Table 7]

【0034】実施例5 任意に選んだ10名のパネラーを用いて、表8に示す2
種の浴用剤について上記と同様に、唾液中のsIgAと
アンケートから好みと免疫機能の変化について検討し
た。色しか違わない2つの処方で、好まれ方が違ってお
り、免疫機能の変化はこの好みを反映している事が判
る。又、この様な機能で測れないメリットを本発明の方
法によれば評価できる事も明かである。
Example 5 2 shown in Table 8 using 10 panelists selected arbitrarily.
Similar to the above, for the various bath agents, changes in taste and immune function were examined from sIgA in saliva and a questionnaire. The two prescriptions that differ only in color differ in how they are preferred, and it can be seen that changes in immune function reflect this preference. It is also clear that the method of the present invention can evaluate the merit that cannot be measured by such a function.

【0035】[0035]

【表8】 [Table 8]

【0036】[0036]

【表9】 [Table 9]

【0037】実施例6 肩こりに悩むパネラー3名について市販のマッサージ機
でマッサージしその前後の免疫状態の変化をsIgAを
指標に上記の方法で測定した。結果はマッサージ後はマ
ッサージ前に比して平均で12%唾液中のsIgAの濃
度が上昇した。これより、本発明の測定法は医療品にも
適用できる事が判る。
Example 6 Three panelists suffering from stiff shoulders were massaged with a commercially available massage machine and changes in the immune status before and after the massage were measured by the above method using sIgA as an index. As a result, after the massage, the concentration of sIgA in saliva was increased by 12% on average as compared with before the massage. From this, it is understood that the measuring method of the present invention can be applied to medical products.

【0038】[0038]

【発明の効果】本発明の測定法によれば、抽象的な概念
であった心地よさを定量的且つ客観的に測定できる。
又、この心地よさを指標にすれば、ソフト的なメリット
も的確に評価できる。
According to the measuring method of the present invention, comfort, which is an abstract concept, can be quantitatively and objectively measured.
In addition, if this comfort is used as an index, the soft merit can be accurately evaluated.

Claims (7)

【特許請求の範囲】[Claims] 【請求項1】 免疫機能の変化を指標とする事を特徴と
する心地よさの測定法。
1. A method for measuring comfort, which is characterized by using a change in immune function as an index.
【請求項2】 免疫機能の変化が唾液中の分泌型免疫グ
ロブリンの濃度の上昇率である、請求項1記載の測定
法。
2. The measuring method according to claim 1, wherein the change in immune function is the rate of increase in the concentration of secretory immunoglobulin in saliva.
【請求項3】 免疫機能の変化が末梢血中のCDレセプ
ターの発現量の上昇率である、請求項1記載の測定法。
3. The assay method according to claim 1, wherein the change in immune function is a rate of increase in the expression level of CD receptor in peripheral blood.
【請求項4】 免疫機能の変化が血液中のナチュラル・
キラー細胞活性の上昇率である請求項1記載の測定法。
4. Changes in immune function are caused by natural
The measuring method according to claim 1, which is a rate of increase in killer cell activity.
【請求項5】 請求項1〜4の何れか一項に記載の測定
法で測定された心地よさを指標とする商品のソフト的メ
リットの評価法。
5. A method for evaluating the soft merit of a product, which uses as an index the comfort measured by the measuring method according to claim 1.
【請求項6】 商品が香粧品である、請求項5記載の測
定方法。
6. The measuring method according to claim 5, wherein the product is a cosmetic product.
【請求項7】 商品が医療品である、請求項5記載の測
定方法。
7. The measuring method according to claim 5, wherein the product is a medical product.
JP1653795A 1995-01-06 1995-01-06 Method for measuring comfortableness Pending JPH08189930A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1653795A JPH08189930A (en) 1995-01-06 1995-01-06 Method for measuring comfortableness

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1653795A JPH08189930A (en) 1995-01-06 1995-01-06 Method for measuring comfortableness

Publications (1)

Publication Number Publication Date
JPH08189930A true JPH08189930A (en) 1996-07-23

Family

ID=11919026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1653795A Pending JPH08189930A (en) 1995-01-06 1995-01-06 Method for measuring comfortableness

Country Status (1)

Country Link
JP (1) JPH08189930A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001026686A1 (en) * 1999-10-08 2001-04-19 Shiseido Company, Ltd. Skin immune function controlling agents
JP2008064722A (en) * 2006-09-11 2008-03-21 Kao Corp Evaluation method of usability of cosmetic material
JP2009161447A (en) * 2007-12-28 2009-07-23 Kao Corp Composition for oral cavity
JP2010048612A (en) * 2008-08-20 2010-03-04 Shiseido Co Ltd Risk evaluation method of "dullness" and "stains"

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001026686A1 (en) * 1999-10-08 2001-04-19 Shiseido Company, Ltd. Skin immune function controlling agents
CN100384474C (en) * 1999-10-08 2008-04-30 株式会社资生堂 Skin immune function controlling agents
JP2008064722A (en) * 2006-09-11 2008-03-21 Kao Corp Evaluation method of usability of cosmetic material
JP4721994B2 (en) * 2006-09-11 2011-07-13 花王株式会社 Method for evaluating the feeling of use of cosmetics
JP2009161447A (en) * 2007-12-28 2009-07-23 Kao Corp Composition for oral cavity
JP2010048612A (en) * 2008-08-20 2010-03-04 Shiseido Co Ltd Risk evaluation method of "dullness" and "stains"

Similar Documents

Publication Publication Date Title
Bonnet et al. An update on molecular cat allergens: Fel d 1 and what else? Chapter 1: Fel d 1, the major cat allergen
Topkas et al. Evaluation of saliva collection devices for the analysis of proteins
Carlen et al. Composition of pellicles formed in vivo on tooth surfaces in different parts of the dentition, and in vitro on hydroxyapatite
Chang The pharmacological basis of anti-IgE therapy
Wybran et al. The human rosette-forming cell as a marker of a population of thymus-derived cells
Rokugo et al. Contact sensitivity to Pityrosporum ovale in patients with atopic dermatitis
Hamilton et al. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy
Brar A review of contact dermatitis
Wollenberg et al. Effects of a protein‐free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients
ATE244299T1 (en) TESTING AND TREATING DEMYELINATING DISEASES SUCH AS MULTIPLE SCLEROSIS
Butler et al. Quantitative and functional deficit of suppressor T cells in children with atopic eczema.
CA2805963A1 (en) A method of treating attention deficit hyperactivity disorder
RING et al. Complement and immunoglobulin deposits in the skin of patients with atopic dermatitis
Ponterius et al. Comparative studies on the allergens of horse dandruff and horse serum
JPH08189930A (en) Method for measuring comfortableness
CN110320368A (en) Diagnostic kit based on TREM2 and its application on diagnosis of Parkinson disease product
Ricci et al. In vitro synthesis of human IgE: reappraisal of a 5-year study
Afferni et al. Detection of specific IgE antibodies in sera from patients with hydatidosis.
Bergbrant et al. The evaluation of various methods and antigens for the detection of antibodies against Pityrosporum ovale in patients with seborrhoeic dermatitis
Baker et al. Differential T‐cell reactivity to the round and oval forms of Pityrosporum in the skin of patients with psoriasis
Takai et al. Modulation of allergenicity of major house dust mite allergens Der f 1 and Der p 1 by interaction with an endogenous ligand
Suzuki et al. Applying surface plasmon resonance to monitor the IgE-mediated activation of human basophils
RU2702736C2 (en) Examination in oral cavity inflammation
Kimura et al. An immunohistochemical analysis of the deposited immunoglobulins or fibrinogen in parakeratotic psoriatic horny layer and pemphigus skin lesions
Munro et al. Assessment of biological activity of immunoglobulin preparations by using opsonized micro-organisms to stimulate neutrophil chemiluminescence.